as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹1,708.0
Change
+71.6 (4.38%)
Open
₹1,654.9
Prev. Close
₹1,636.4
Day High
₹1,712.9
Day Low
₹1,624.0
Volume Analysis
Traded
160,966
Delivered
68,392
Delivery %
42.49%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Trading within 3% of its 52-week high (₹1666.0)
Weaknesses (1)
- •Promoter holding is falling
Opportunities (3)
- •Strong 3-year EPS growth (35.8%)
- •Strong 3-year revenue growth (32.2%)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹1,828.16 | ₹1,770.53 | ₹1,739.26 | ₹1,681.63 | ₹1,650.36 | ₹1,592.73 | ₹1,561.46 |
| Fibonacci | ₹1,770.53 | ₹1,736.57 | ₹1,715.59 | ₹1,681.63 | ₹1,647.67 | ₹1,626.69 | ₹1,592.73 |
| Camarilla | ₹1,732.45 | ₹1,724.3 | ₹1,716.15 | ₹1,681.63 | ₹1,699.85 | ₹1,691.7 | ₹1,683.55 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
—
1 Week
+11.83%
1 Month
+25.05%
3 Months
+19.06%
6 Months
—
1 Year
—
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹221.05
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
17.34%
Net margin 6.09% × asset turnover 1.13x × equity multiplier 2.52x
Company Overview
Sector
Healthcare
Market Cap
₹2,548 Cr
P/E (TTM)
48.1
ROE
15.6%
Book Value
₹196.0
Face Value
₹10.0
Source: Screener.in (Consolidated figures) — data as of 16 Nov 2026. Not investment advice.
TopFund Analysis
Fredun Pharmaceuticals L lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 58/100. The strongest factor is Growth (100/100), while Cash Flow (1/100) is the weakest area to weigh before deciding. Notably: Trading within 3% of its 52-week high (₹1666.0); promoter holding is falling. Strong 3-year EPS growth (35.8%).
TopFund Score — Fundamentals Quality
58/100 — AverageData confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Debtor days have improved from 97.8 to 53.2 days.
- −Stock is trading at 7.61 times its book value
- −Promoter holding has decreased over last quarter: -0.95%
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Audio recording of Q2 and H1 FY27 earnings conference call released on 16 November 2026.
CARE report dated Nov. 13, 2026 flags 10-25% deviation in Rs 153.25 crore preferential issue proceeds.
Fredun Pharmaceuticals reports no deviation in use of ₹128.78 crore preferential issue proceeds for quarter ended 30 September 2026.
Intimation of Earnings Conference Call for the Quarter Q2 of FY27
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2023 (S) | Dec 2023 (S) | Mar 2024 (S) | Jun 2024 (S) | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 82 | 87 | 118 | 79 | 0 | 167 | 120 | 145 | 161 | 213 | 228 | 268 |
| Expenses + | 72 | 76 | 107 | 68 | 0 | 150 | 103 | 123 | 135 | 184 | 196 | 225 |
| Operating Profit | 10 | 11 | 11 | 10 | 0 | 17 | 17 | 22 | 26 | 29 | 33 | 42 |
| OPM % | 12.0% | 12.0% | 9.0% | 13.0% | — | 10.0% | 14.0% | 15.0% | 16.0% | 14.0% | 14.0% | 16.0% |
| Other Income + | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 3 | 4 | 4 | 4 | 0 | 8 | 7 | 8 | 11 | 14 | 9 | 9 |
| Depreciation | 1 | 1 | 1 | 1 | 0 | 2 | 1 | 2 | 2 | 3 | 4 | 4 |
| Profit before tax | 6 | 6 | 6 | 6 | 0 | 7 | 9 | 13 | 14 | 11 | 21 | 30 |
| Tax % | 32.0% | 27.0% | 13.0% | 25.0% | — | 17.0% | 25.0% | 26.0% | 25.0% | 4.0% | 36.0% | 37.0% |
| Net Profit + | 4 | 4 | 5 | 4 | 0 | 6 | 7 | 9 | 10 | 11 | 13 | 19 |
| EPS in Rs | 3 | 3 | 4 | 3 | 0 | 4 | 5 | 7 | 7 | 7 | 8 | 11 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | 17 | 12 | 48 | 27 | — | — | — | — | — | 27 | 90 | 84 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 (S) | Mar 2021 (S) | Mar 2022 (S) | Mar 2023 (S) | Mar 2024 (S) | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 25 | 42 | 57 | 60 | 97 | 113 | 134 | 222 | 275 | 348 | 454 | 635 | 870 |
| Expenses + | 24 | 38 | 53 | 54 | 87 | 104 | 126 | 208 | 247 | 310 | 401 | 545 | 740 |
| Operating Profit | 2 | 4 | 3 | 6 | 10 | 8 | 8 | 14 | 28 | 38 | 52 | 91 | 130 |
| OPM % | 7.0% | 9.0% | 6.0% | 10.0% | 11.0% | 7.0% | 6.0% | 6.0% | 10.0% | 11.0% | 12.0% | 14.0% | 15.0% |
| Other Income + | 0 | 1 | 2 | 0 | 0 | 1 | 1 | 2 | 2 | 1 | 2 | 4 | 0 |
| Interest | 1 | 2 | 2 | 2 | 3 | 4 | 4 | 5 | 9 | 14 | 22 | 39 | 42 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 3 | 4 | 5 | 8 | 12 |
| Profit before tax | 1 | 2 | 2 | 3 | 6 | 2 | 3 | 9 | 18 | 21 | 27 | 47 | 75 |
| Tax % | 52.0% | 42.0% | 36.0% | 34.0% | 28.0% | 24.0% | 37.0% | 26.0% | 38.0% | 27.0% | 28.0% | 31.0% | — |
| Net Profit + | 0 | 1 | 1 | 2 | 4 | 2 | 2 | 6 | 11 | 16 | 20 | 33 | 53 |
| EPS in Rs | 0 | 2 | 2 | 2 | 4 | 2 | 2 | 5 | 8 | 11 | 14 | 20 | 32 |
| Dividend Payout % | 0.0% | 13.0% | 10.0% | 12.0% | 6.0% | 14.0% | 14.0% | 5.0% | 3.0% | 2.0% | 2.0% | 1.0% | — |
| Sales growth | 19 | 67 | 34 | 5 | 63 | 16 | 19 | 66 | 24 | 27 | — | 40 | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 (S) | Mar 2021 (S) | Mar 2022 (S) | Mar 2023 (S) | Mar 2024 (S) | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 0 | 1 | 2 | 19 | 35 | 37 | 39 | 64 | 92 | 117 | 137 | 273 | 314 |
| Borrowings + | 9 | 16 | 21 | 10 | 19 | 35 | 40 | 53 | 87 | 106 | 167 | 222 | 253 |
| Other Liabilities + | 11 | 24 | 30 | 47 | 47 | 65 | 79 | 66 | 74 | 81 | 179 | 142 | 190 |
| Total Liabilities | 23 | 43 | 56 | 79 | 105 | 141 | 162 | 187 | 257 | 308 | 487 | 642 | 774 |
| Fixed Assets + | 8 | 15 | 16 | 16 | 31 | 31 | 30 | 32 | 39 | 47 | 53 | 118 | 153 |
| CWIP | 1 | 0 | 4 | 11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 3 |
| Other Assets + | 14 | 29 | 36 | 52 | 74 | 110 | 131 | 155 | 218 | 260 | 433 | 522 | 619 |
| Total Assets | 23 | 43 | 56 | 79 | 105 | 141 | 162 | 187 | 257 | 308 | 487 | 642 | 774 |
| Equity Capital | 2 | 2 | 2 | 3 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 17 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 (S) | Mar 2021 (S) | Mar 2022 (S) | Mar 2023 (S) | Mar 2024 (S) | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 2 | 3 | 4 | 17 | 1 | -11 | 0 | -2 | -14 | 0 | -17 | 12 |
| Cash from Investing Activity + | -3 | -6 | -7 | -8 | -5 | -1 | -1 | -4 | -9 | -8 | -6 | -74 |
| Cash from Financing Activity + | 1 | 3 | 3 | -8 | 4 | 14 | -1 | 7 | 25 | 6 | 27 | 121 |
| Net Cash Flow | 0 | 1 | -1 | 1 | 0 | 2 | -2 | 1 | 1 | -2 | 4 | 60 |
| Free Cash Flow | -1 | -3 | -3 | 9 | -4 | -12 | -1 | -7 | -24 | -8 | -23 | -62 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 108 | 85 | 117 | 303 | 8 | -128 | 2 | -17 | -52 | -1 | -32 | 13 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 49.24% | 49.24% | 49.23% | 49.47% | 49.47% | 49.47% | 49.49% | 49.46% | 53.0% | 51.94% | 51.45% | 52.25% |
| Promoters | 49.16% | 49.17% | 49.17% | 48.93% | 48.93% | 48.93% | 48.93% | 48.93% | 43.06% | 44.17% | 44.57% | 43.62% |
| FII | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.01% | 0.46% | 1.06% | 1.06% | 0.69% |
| DII | 1.6% | 1.6% | 1.6% | 1.59% | 1.59% | 1.59% | 1.59% | 1.61% | 3.48% | 2.83% | 2.94% | 3.43% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Fredun Pharmaceuticals L (this stock) | 2,548 | 48.1 | 7.59 | 15.6% |
| Hikal Limited | 2,690 | 37.8 | 2.28 | 2.21% |
| Vimta Labs Limited | 2,230 | 36.7 | 6.46 | 13.5% |
| Ind Swift Laboratories Lt | 2,881 | 31.4 | 1.95 | 4.02% |
| Sai Parenterals Limited | 2,189 | 87.8 | 4.42 | 4.88% |
| Dishman Carbo Amcis Ltd | 2,183 | 151.0 | 0.33 | 1.58% |
| Sakar Healthcare Limited | 2,172 | 50.7 | 6.26 | 9.99% |
Which Mutual Funds Hold Fredun Pharmaceuticals L?
Frequently Asked Questions about Fredun Pharmaceuticals L
Fredun Pharmaceuticals L (FREDUN) closed at ₹1,708.0 on NSE on 19 November 2026, up 71.6 (4.38%) from the previous close.
Fredun Pharmaceuticals L trades on the NSE (National Stock Exchange of India) under the symbol FREDUN.
Fredun Pharmaceuticals L has a trailing twelve-month P/E (price-to-earnings) ratio of 48.1.
Fredun Pharmaceuticals L has a dividend yield of 0.02%.
Fredun Pharmaceuticals L's 52-week high is ₹1,666.0 and its 52-week low is ₹454.0.
Fredun Pharmaceuticals L has a market capitalisation of ₹2,548 crore.
Fredun Pharmaceuticals L has a TopFund Quality Score of 58/100 (Average), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Fredun Pharmaceuticals L?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.